Viva Biotech Holdings
Viva Biotech Holdings is a China-based contract research organization providing structure-based drug discovery and integrated CRO/CDMO services to biotech and pharmaceutical clients worldwide.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Viva Biotech Holdings (维亚生物科技控股集团) is a China-headquartered life-sciences services company that built its reputation on structure-based drug discovery. Founded in 2008 and headquartered in Shanghai, the company began as a fragment-based and structure-based early discovery specialist serving global pharmaceutical and biotechnology clients, and it has since expanded into an integrated platform spanning discovery biology, medicinal chemistry, protein science, and later-stage development and manufacturing services. The company's core offering is contract research: it works with biotech startups and large pharma on hit finding, lead optimization, structural biology, and preclinical development, often in exchange for service fees plus equity or milestone arrangements with early-stage biotech clients. This "service-for-equity" model became a distinctive part of Viva Biotech's positioning, giving it exposure to the upside of the biotech companies it supports while funding its own platform expansion. Viva Biotech is listed on the Hong Kong Stock Exchange under the ticker 1873.HK, having completed its IPO in 2019. The listing gave the company capital to expand its service portfolio, including investments in chemistry, manufacturing and controls (CMC) and CDMO capabilities, and to broaden its international footprint with operations and business development presence in the United States and Europe alongside its Chinese laboratories. Its client base is global, with a strong concentration in early-stage and emerging biotech companies in China, the United States, and Europe. The company positions itself as a partner for innovators seeking an integrated path from structural biology through to candidate selection and beyond, competing in the global CRO and drug-discovery services market. Note: the supplied evidence snippet does not discuss Viva Biotech; it is an unrelated news article about an OpenAI product. The details above reflect well-established public information about the company and should be verified against primary sources before publication.
History
Viva Biotech Holdings was established in 2008 in Shanghai as a structure-based drug discovery services company. Its founding team built the business around fragment-based screening and structural biology, capabilities that were relatively scarce among Chinese service providers at the time and that appealed to Western biotech and pharmaceutical clients seeking early discovery expertise. Through the 2010s the company expanded its scientific platform, adding medicinal chemistry, protein expression and purification, assay development, and structural biology at scale. A defining feature of its business model was the willingness to take equity stakes or milestone interests in early-stage biotech clients in exchange for discounted or deferred service fees — the so-called service-for-equity model — which allowed cash-constrained startups to access discovery services while giving Viva Biotech a portfolio of upside exposures. In 2019 Viva Biotech completed an initial public offering on the Hong Kong Stock Exchange, listing under the stock code 1873.HK. The IPO proceeds supported expansion of its service capabilities and facilities, including investment in downstream development and manufacturing capabilities to complement its discovery franchise, and supported international business development in the United States and Europe. After listing, the company pursued an integrated-platform strategy, building out CMC and CDMO capabilities and incubating or investing in biotech ventures alongside its core contract research business. It also expanded its client base among emerging Chinese biotech companies while maintaining a significant share of overseas revenue. Note: the supplied evidence snippet is unrelated to Viva Biotech (it concerns an OpenAI product announcement). The history above is based on well-established public information and should be verified against primary sources such as the company's prospectus and annual reports before publication.
- 2019
Completed initial public offering on the Hong Kong Stock Exchange (1873.HK).
- 2008
Viva Biotech founded in Shanghai as a structure-based drug discovery services company.
Products and positioning
Integrated structure-based drug discovery CRO and CDMO partner for global biotech and pharmaceutical innovators.
Structure-based drug discovery services
Medicinal chemistry and lead optimization
CMC and CDMO services
Recent events
- Unconfirmed
Viva Biotech Upgrades MARS Multimodal Algorithm Platform[2]
Reported:
During the reporting period, Viva Biotech's CADD/AIDD team upgraded and launched the MARS multimodal comprehensive algorithm platform, with the core Pep2MARS algorithm platform establishing technical barriers in peptides, cyclic peptides and complex macrocyclic compounds. The platform upgraded three underlying modules, V-Scepter, V-Orb and V-Mantle.
Viva Biotech Reports 2026 Interim Results[2]
Reported:
Viva Biotech Holdings (1873.HK) reported interim results for the six months ended June 30, 2026, with total revenue of RMB 1,006.5 million, up 21.0% year on year, gross profit of RMB 341.7 million, up 0.7%, and gross margin of 34.0%. Net profit was RMB 100.9 million and adjusted non-IFRS net profit was RMB 128.3 million, both down from the prior-year period, mainly due to lower investment income, unfavorable foreign exchange movements and higher R&D expenses from new business initiatives. CRO revenue was RMB 405.1 million and Langhua Pharmaceutical CDMO revenue was RMB 601.4 million, up about 47.0% year on year.
Viva Biotech reports 2021 interim results[3]
Reported:
Viva Biotech announced its interim results for the six months ended June 30, 2021, reporting revenue of approximately RMB1,026.5 million, gross profit of approximately RMB316.3 million, and adjusted net profit of approximately RMB204.9 million.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/维亚生物科技控股集团 · Editorial policy · How profiles are compiled